ENDEAVOR: A phase 3 study of carfilzomib and dexamethasone versus bortezomib and dexamethasone in patients with relapsed multiple myeloma | Dr Jesús San Miguel at EHA 2015
At the 20th Congress of the European Hematology Association (EHA), Jesús F. San Miguel, MD, of the Clínica Universidad de Navarra, Navarra, Spain, discusses the results of the multicentre, open-label,...
Author: EMJ
Added: 06/25/2015 (Source: Oncology Tube)
Source: Oncology Tube - June 25, 2015 Category: Cancer & Oncology Source Type: podcasts
Bortezomib's Impact on Treatment of MCL
The impact of the approval of frontline bortezomib for the treatment of mantle cell lymphoma (MCL).
Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center,
Author: onclivetv
Added: 03/30/2015 (Source: Oncology Tube)
Source: Oncology Tube - March 30, 2015 Category: Cancer & Oncology Source Type: podcasts
Understanding Velcade
An eight-minute video explaining what you need to know about VELCADE SQ.
Please subscribe to our channel!
Subscribe to International Myeloma Foundation: http://bit.ly/XlUtPE...
Visit our website a...
Author: feeds
Added: 02/24/2015 (Source: Oncology Tube)
Source: Oncology Tube - February 24, 2015 Category: Cancer & Oncology Source Type: podcasts
Case 1: Standard-risk, Younger Double Refractory Patient
Patients with multiple myeloma that is refractory to both bortezomib and lenalidomide have an especially poor prognosis. This double-refractory indication is emerging as a significant clinical challen...
Author: imedex
Added: 06/05/2014 (Source: Oncology Tube)
Source: Oncology Tube - June 5, 2014 Category: Cancer & Oncology Source Type: podcasts
Case 2: Double Refractory Patient with High-risk Cytogenetics
Patients with multiple myeloma that is refractory to both bortezomib and lenalidomide have an especially poor prognosis. This double-refractory indication is emerging as a significant clinical challen...
Author: imedex
Added: 06/05/2014 (Source: Oncology Tube)
Source: Oncology Tube - June 5, 2014 Category: Cancer & Oncology Source Type: podcasts
Case 3: Elderly Double Refractory Patient with Renal Impairment
Patients with multiple myeloma that is refractory to both bortezomib and lenalidomide have an especially poor prognosis. This double-refractory indication is emerging as a significant clinical challen...
Author: imedex
Added: 06/05/2014 (Source: Oncology Tube)
Source: Oncology Tube - June 5, 2014 Category: Cancer & Oncology Source Type: podcasts
Multiple Myeloma - Case Presentations
Dr. James Berenson discusses two cases: 1) a myeloma patient who has relapsed after frontline therapy, and 2) a myeloma patient who is refractory to both bortezomib and lenalidomide.
This webcast w...
Author: imedex
Added: 01/18/2014 (Source: Oncology Tube)
Source: Oncology Tube - January 19, 2014 Category: Cancer & Oncology Source Type: podcasts
Treatment Response Rates Following a Myeloma Relapse
Will certain myeloma drugs respond well if used again for relapse? A patient poses a question about relapse and whether Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasonealone (Decadron) ...
Author: patientpower
Added: 12/12/2013 (Source: Oncology Tube)
Source: Oncology Tube - December 13, 2013 Category: Cancer & Oncology Source Type: podcasts
